{"drugs":["Conjugated Estrogens","Premarin","Premarin Vaginal"],"mono":[{"id":"214370-s-0","title":"Generic Names","mono":"Conjugated Estrogens"},{"id":"214370-s-1","title":"Dosing and Indications","sub":{"0":{"id":"214370-s-1-4","title":"Adult Dosing","mono":"<ul><li>in postmenopausal women with a uterus, a progestin should be added to estrogen therapy to reduce the risk of endometrial cancer<\/li><li>prescribe the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual women; re-evaluate at 3- to 6-month intervals to determine if treatment is still necessary<\/li><li><b>Abnormal vasomotor function (Moderate to Severe) - Menopause:<\/b> initial, 0.3 mg ORALLY daily (continuously or cyclically) and adjust dose based upon individual patient response<\/li><li><b>Atrophic vulva - Atrophy of vagina:<\/b> initial, 0.3 mg ORALLY daily (continuously or cyclically) and adjust dose depending upon the tissue response of the patient<\/li><li><b>Atrophic vulva - Atrophy of vagina:<\/b> initial, 0.5 g INTRAVAGINALLY daily for 21 days, off for 7 days; may increase to 2 g based on clinical response<\/li><li><b>Carcinoma of prostate, Advanced, androgen-dependent; for palliation only:<\/b> 1.25 to 2.5 mg ORALLY three times daily<\/li><li><b>Decreased estrogen level, Secondary to castration or primary ovarian failure:<\/b> 1.25 mg ORALLY daily, cyclically (eg, 3 weeks on, 1 week off); adjust dose according to severity of symptoms and response; adjust to lowest most effective dose<\/li><li><b>Decreased estrogen level - Female hypogonadism syndrome:<\/b> 0.3 or 0.625 mg ORALLY daily given cyclically (eg, 3 weeks on, 1 week off); adjust dose depending on the severity of symptoms and responsiveness of endometrium<\/li><li><b>Dysfunctional uterine bleeding, Due to hormonal imbalance in the absence of organic pathology:<\/b> 25 mg IV or IM, may repeat in 6 to 12 hours if necessary<\/li><li><b>Dyspareunia (Moderate to Severe) - Menopause:<\/b> cyclic regimen: 0.5 g INTRAVAGINALLY once daily for 21 days, then off for 7 days<\/li><li><b>Dyspareunia (Moderate to Severe) - Menopause:<\/b> continuous regimen: 0.5 g INTRAVAGINALLY twice a week continuously<\/li><li><b>Gender identity disorder - Male-to-female transsexual:<\/b> various doses and preparations used in clinical trials including conjugated estrogens 1.25 to 10 mg ORALLY daily<\/li><li><b>Metastatic breast cancer, Palliation only, in appropriately selected women and men with metastatic disease:<\/b> 10 mg ORALLY 3 times daily for at least 3 months<\/li><li><b>Postmenopausal osteoporosis; Prophylaxis:<\/b> initial, 0.3 mg ORALLY daily given continuously or in cyclical regimens (eg, 25 days on, 5 days off); adjust dose based upon the individual clinical and bone mineral density responses; adjust to lowest level that provides effective control<\/li><\/ul>"},"1":{"id":"214370-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>safety and efficacy of oral conjugated estrogen in children not established; however, estrogen therapy has been used for the induction of puberty in adolescents with some forms of pubertal delays<\/li><li>conjugated estrogen vaginal cream is not indicated for use in children<\/li><\/ul>"},"3":{"id":"214370-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Abnormal vasomotor function (Moderate to Severe) - Menopause<\/li><li>Atrophic vulva - Atrophy of vagina<\/li><li>Carcinoma of prostate, Advanced, androgen-dependent; for palliation only<\/li><li>Decreased estrogen level, Secondary to castration or primary ovarian failure<\/li><li>Decreased estrogen level - Female hypogonadism syndrome<\/li><li>Dysfunctional uterine bleeding, Due to hormonal imbalance in the absence of organic pathology<\/li><li>Dyspareunia (Moderate to Severe) - Menopause<\/li><li>Metastatic breast cancer, Palliation only, in appropriately selected women and men with metastatic disease<\/li><li>Postmenopausal osteoporosis; Prophylaxis<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Bleeding - Renal failure<\/li><li>Gender identity disorder - Male-to-female transsexual<\/li><li>Hemorrhagic cystitis<\/li><li>Postcoital contraception<\/li><li>Postoperative hemorrhage<\/li><li>Turner syndrome<\/li><\/ul>"}}},{"id":"214370-s-2","title":"Black Box Warning","mono":"<ul><li><b>Intravenous (Powder for Solution)<\/b><br\/>Estrogens increase the risk of endometrial cancer; monitor for abnormal vaginal bleeding. Estrogens with or without progestins should not be used for the prevention of cardiovascular disease or dementia. Increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and DVT in postmenopausal women (50 to 79 years of age) have been reported. An increased risk of developing probable dementia in postmenopausal women 65 years of age or older has also been reported.<br\/><\/li><li><b>Oral (Tablet)<\/b><br\/>Unopposed estrogens increase the risk of endometrial cancer. Adding a progestin will reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Diagnostic measures should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding. Estrogens with or without progestins should not be used for the prevention of cardiovascular disease or dementia. Increased risks of stroke and deep vein thrombosis in postmenopausal women (50 to 79 years of age) using estrogen alone have been reported. Increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women (50 to 79 years of age) using estrogens combined with progestins have been reported. An increased risk of developing probable dementia in postmenopausal women 65 years of age or older has also been reported in women receiving estrogen alone or estrogen combined with progestins. Risks should be assumed to be similar for other doses, combinations, and dosage forms of estrogens and progestins. Estrogens, with or without progestins, should be prescribed at the lowest effective doses and for the shortest duration possible.<br\/><\/li><li><b>Vaginal (Cream)<\/b><br\/>Estrogens increase the risk of endometrial cancer; monitor for abnormal genital bleeding. Adding a progestin to estrogen therapy may reduce endometrial hyperplasia, a precursor to endometrial cancer. Estrogens with or without progestins should not be used for the prevention of cardiovascular disease or dementia. Increased risks of DVT, pulmonary embolism, stroke and myocardial infarction in postmenopausal women (50 to 79 years of age) and increased risks of developing probable dementia in postmenopausal women 65 years of age or older have been reported with estrogen-alone therapy and with estrogen plus progestin therapy. An increased risk of invasive breast cancer has also been reported with estrogen plus progestin therapy.<br\/><\/li><\/ul>"},{"id":"214370-s-3","title":"Contraindications\/Warnings","sub":[{"id":"214370-s-3-9","title":"Contraindications","mono":"<ul><li>anaphylactic reaction or angioedema to conjugated estrogens, known<\/li><li>arterial thromboembolic disease, active, recent, or history (eg, stroke, myocardial infarction)<\/li><li>breast cancer, known, suspected, or history; except in appropriately selected patients being treated for metastatic disease<\/li><li>DVT\/pulmonary embolism, active or history<\/li><li>estrogen-dependent neoplasia, known or suspected<\/li><li>genital bleeding, undiagnosed abnormal<\/li><li>hypersensitivity to conjugated estrogens or any other component of the product<\/li><li>liver dysfunction or disease, known<\/li><li>pregnancy, known or suspected<\/li><li>protein C, protein S, antithrombin deficiency, or other known thrombophilic disorders<\/li><\/ul>"},{"id":"214370-s-3-10","title":"Precautions","mono":"<ul><li>cardiovascular disorders; estrogens with or without progestins should not be used for the prevention of cardiovascular disease<\/li><li>dementia; increased risk of with estrogen-alone and with conjugated estrogen plus progestin therapy in postmenopausal women aged 65 years and older; do not use for the prevention of dementia<\/li><li>endometrial cancer; increased risk of with unopposed estrogen use in women with intact uteri<\/li><li>myocardial infarction, stroke, invasive breast cancer, pulmonary emboli and deep vein thrombosis; conjugated estrogens plus progestin increase the risk in postmenopausal women aged 50 to 79 years; discontinue immediately if suspected<\/li><li>stroke and deep vein thrombosis; conjugated estrogens alone increased the risk in postmenopausal women aged 50 to 79 years; discontinue immediately if suspected<\/li><li>addition of a progestin to estrogen therapy; lowers incidence of endometrial hyperplasia in women with a uterus but may also increase risk of breast cancer, affect lipoprotein metabolism, and impair glucose tolerance<\/li><li>anaphylaxis and angioedema within minutes to hours after administration have been reported during postmarketing surveillance<\/li><li>arterial vascular disease risk factors (eg, hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, obesity); manage appropriately<\/li><li>asthma, diabetes mellitus, epilepsy, migraine, porphyria, systemic lupus erythematosus, and hepatic hemangiomas; may cause exacerbation<\/li><li>barrier contraceptives; conjugated estrogens vaginal cream may weaken latex condoms and may contribute to the failure of condoms, diaphragms, or cervical caps made of latex or rubber<\/li><li>breast cancer and bone metastases; increased risk for severe hypercalcemia<\/li><li>conditions affected by fluid retention (eg, cardiac or renal dysfunction); estrogens may exacerbate condition<\/li><li>endometriosis, preexisting; may cause exacerbation<\/li><li>gallbladder disease requiring surgery has been reported; estrogen increases risk 2- to 4-fold in postmenopausal women<\/li><li>hepatic impairment or history of cholestatic jaundice; may decrease estrogen metabolism; discontinue with recurrence<\/li><li>hereditary angioedema; may cause exacerbation<\/li><li>hypertension; exacerbation may occur<\/li><li>hypertriglyceridemia, preexisting; may elevate plasma triglycerides leading to pancreatitis; possible discontinuation recommended<\/li><li>hypocalcemia, severe, preexisting; may exacerbate condition<\/li><li>hypoparathyroidism, preexisting; increased risk of estrogen-induced hypocalcemia<\/li><li>hypothyroidism, preexisting; estrogen increases thyroid-binding globulin levels; monitoring recommended<\/li><li>ovarian cancer; increased risk with estrogens with or without progestin<\/li><li>prepubertal girls and boys; in girls, may induce premature breast development, vaginal cornification, and vaginal bleeding; in boys, may modify the normal pubertal process and induce gynecomastia; large and repeated doses of estrogen over an extended time period may accelerate epiphyseal closure, which could result in short adult stature if treatment is initiated before the completion of physiologic puberty in normally developing children<\/li><li>prolonged therapy; increased risk of breast cancer<\/li><li>retinal vascular thrombosis has been reported; discontinue if there is sudden partial or complete loss of vision, or a sudden onset of proptosis, diplopia, or migraine<\/li><li>surgeries that are associated with increased risk of thromboembolism or periods of prolonged immobilization; increased risk of thromboembolism; drug discontinuation is recommended 4 to 6 weeks before procedure<\/li><li>venous thromboembolism risk factors (eg, personal or family history, obesity, systemic lupus erythematosus); increased risk of cardiovascular disorders<\/li><\/ul>"},{"id":"214370-s-3-11","title":"Pregnancy Category","mono":"<ul><li>X (FDA)<\/li><li>D (AUS)<\/li><\/ul>"},{"id":"214370-s-3-12","title":"Breast Feeding","mono":"<ul><li>WHO: Avoid breastfeeding if possible.  May inhibit lactation.<\/li><li>Micromedex: Milk effects are possible.<\/li><\/ul>"}]},{"id":"214370-s-4","title":"Drug Interactions","sub":{"1":{"id":"214370-s-4-14","title":"Major","mono":"<ul><li>Bupropion (theoretical)<\/li><li>Dasabuvir (theoretical)<\/li><li>Donepezil (theoretical)<\/li><li>Paritaprevir (theoretical)<\/li><\/ul>"},"2":{"id":"214370-s-4-15","title":"Moderate","mono":"<ul><li>Clarithromycin (probable)<\/li><li>Etoricoxib (probable)<\/li><li>Ginseng (probable)<\/li><li>Itraconazole (probable)<\/li><li>Ketoconazole (probable)<\/li><li>Levothyroxine (probable)<\/li><li>Licorice (probable)<\/li><li>St John's Wort (probable)<\/li><li>Tipranavir (established)<\/li><\/ul>"}}},{"id":"214370-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Edema, Vasodilatation (vaginal cream, 21 days on\/7 off regimen, 3.5%; 2 times\/wk regimen, 5%)<\/li><li><b>Dermatologic:<\/b>Chloasma, Hirsutism, Injection site reaction, Pruritus (5%)<\/li><li><b>Endocrine metabolic:<\/b>Weight change finding<\/li><li><b>Gastrointestinal:<\/b>Abdominal pain (vaginal cream, 21 days on\/7 off regimen, 7.7%; 2 times\/wk regimen, 6.4%), Bloating symptom, Diarrhea (vaginal cream, 21 days on\/7 off regimen, 2.8%; 2 times\/wk regimen, 7.1%), Flatulence (7%), Nausea (oral, 9%; vaginal cream, 21 days on\/7 off regimen, 3.5%; 2 times\/wk regimen, 2.1%), Stomach cramps, Vomiting<\/li><li><b>Musculoskeletal:<\/b>Backache (vaginal cream, 21 days on\/7 off regimen, 4.9%; 2 times\/wk regimen, 9.3%), Leg cramp<\/li><li><b>Neurologic:<\/b>Asthenia (vaginal cream, 21 days on\/7 off regimen, 5.6%; 2 times\/wk regimen, 1.4%), Headache (vaginal cream, 21 days on\/7 off regimen, 11.2%; 2 times\/wk regimen, 17.9%), Migraine<\/li><li><b>Psychiatric:<\/b>Depression, Disturbance in mood<\/li><li><b>Reproductive:<\/b>Disorder of menstruation, Pain of breast (oral, 12%; vaginal cream, 21 days on\/7 off regimen, 5.6%; 2 times\/wk regimen, 2.9%), Swelling of breast, Vaginitis (vaginal cream, 21 days on\/7 off regimen, 5.6%; 2 times\/wk regimen, 5%), Withdrawal bleeding<\/li><li><b>Respiratory:<\/b>Increasing frequency of cough (vaginal cream, 21 days on\/7 off regimen, 0%; 2 times\/wk regimen, 5%), Pharyngitis (vaginal cream, 21 days on\/7 off regimen, 2.1%; 2 times\/wk regimen, 5%)<\/li><li><b>Other:<\/b>Accidental injury (vaginal cream, 21 days on\/7 off regimen, 2.8%; 2 times\/wk regimen, 6.4%), Disorder of skin appendage (vaginal cream, 21 days on\/7 off regimen, 8.4%; 2 times\/wk regimen, 11.4%), Infectious disease (vaginal cream, 21 days on\/7 off regimen, 4.9%; 2 times\/wk regimen, 11.4%), Pain (vaginal cream, 21 days on\/7 off regimen, 7%; 2 times\/wk regimen, 2.9%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Heart disease, Hypertension, Myocardial infarction<\/li><li><b>Endocrine metabolic:<\/b>Body fluid retention, Breast cancer, Diabetes mellitus, Hypercalcemia<\/li><li><b>Gastrointestinal:<\/b>Disorder of gallbladder, Pancreatitis<\/li><li><b>Hematologic:<\/b>Venous thrombosis<\/li><li><b>Immunologic:<\/b>Anaphylaxis<\/li><li><b>Neurologic:<\/b>Cerebrovascular accident, Dementia, Impaired cognition<\/li><li><b>Ophthalmic:<\/b>Thrombosis of retinal vein<\/li><li><b>Reproductive:<\/b>Cervical cancer, Malignant neoplasm of endometrium of corpus uteri, Ovarian cancer<\/li><li><b>Respiratory:<\/b>Pulmonary embolism<\/li><li><b>Other:<\/b>Angioedema, Breast cancer, Cervical cancer, Malignant neoplasm of endometrium of corpus uteri, Ovarian cancer<\/li><\/ul>"},{"id":"214370-s-6","title":"Drug Name Info","sub":{"0":{"id":"214370-s-6-17","title":"US Trade Names","mono":"<ul><li>Premarin<\/li><li>Premarin Vaginal<\/li><\/ul>"},"2":{"id":"214370-s-6-19","title":"Class","mono":"<ul><li>Endocrine-Metabolic Agent<\/li><li>Estrogen<\/li><li>Female Reproductive Agent<\/li><\/ul>"},"3":{"id":"214370-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"214370-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},{"id":"214370-s-7","title":"Mechanism Of Action","mono":"Estrogens bind to nuclear receptors in estrogen-responsive tissues. It modulates the pituitary secretion of the gonadotropins, luteinizing hormone (LH) and follicle stimulating hormone (FSH), through a negative feedback mechanism reducing the levels of these hormones seen in postmenopausal women .<br\/>"},{"id":"214370-s-8","title":"Pharmacokinetics","sub":[{"id":"214370-s-8-23","title":"Absorption","mono":"<ul><li>Oral, well absorbed<\/li><li>Effect of food: not significant<\/li><\/ul>"},{"id":"214370-s-8-24","title":"Distribution","mono":"<ul><li>Vd: widely distributed<\/li><li>Protein binding: largely bound to sex hormone-binding globulin and albumin<\/li><\/ul>"},{"id":"214370-s-8-25","title":"Metabolism","mono":"<ul><li>Hepatic; partially by P450 CYP3A4<\/li><li>Metabolites: estrone, estriol, and estrone sulfate<\/li><\/ul>"},{"id":"214370-s-8-26","title":"Excretion","mono":"<ul><li>Renal, primary<\/li><li>Biliary: conjugates secreted into the intestine<\/li><\/ul>"},{"id":"214370-s-8-27","title":"Elimination Half Life","mono":"<ul><li>Estrone: oral, 26.5 to 26.7 hr<\/li><li>Baseline adjusted total estrone: oral, 14.8 hr to 17.5 hr<\/li><li>Equilin: oral, 11.4 to 12.5 hr<\/li><\/ul>"}]},{"id":"214370-s-9","title":"Administration","mono":"<ul><li><b>Intravenous<\/b><br\/><ul><li>to reconstitute, slowly introduce 5 mL of Sterile Water for Injection, USP against the side of the vial and agitate gently; do not shake violently<\/li><li>use immediately after reconstitution<\/li><li>administration of the intravenous injection should be made slowly to obviate the occurrence of flushes<\/li><li>administration of intravenous conjugated estrogens with other agents is not recommended except in emergencies when it may be administered into tubing distal to the infusion needle of another infusion<\/li><li>may administer with normal saline, dextrose, and invert sugar solutions; avoid administration with any solution that has an acid pH<\/li><\/ul><\/li><li><b>Oral<\/b><br\/>may be taken without regard to meals<br\/><\/li><li><b>Vaginal<\/b><br\/><ul><li>use calibrated applicator provided<\/li><li>to clean applicator wash with mild soap and warm water; do NOT use hot water or boil<\/li><\/ul><\/li><\/ul>"},{"id":"214370-s-10","title":"Monitoring","mono":"<ul><li>abnormal uterine bleeding (IV): decreased bleeding and clinical response<\/li><li>advanced androgen-dependent prostate cancer: phosphatase levels<\/li><li>female castration: severity of symptoms and patient response<\/li><li>female hypogonadism: serum estradiol and follicle stimulating hormone levels; severity of symptoms; endometrial response<\/li><li>postmenopausal osteoporosis, prevention: periodic assessments of individual clinical and bone mineral density responses<\/li><li>postmenopausal vasomotor symptoms: individual clinical response and severity of symptoms<\/li><li>postmenopausal vulvar and vaginal atrophy: individual clinical response and severity of symptoms<\/li><li>blood pressure at regular intervals<\/li><li>bone maturation and effects on epiphyseal centers; periodically in patients whose bone growth in not complete<\/li><li>breast exam, yearly in addition to monthly self-exam; mammogram based on age, risk factors and prior results<\/li><li>endometrial sampling in all cases of undiagnosed persistent or recurring abnormal vaginal bleeding<\/li><li>eye exam in cases of sudden visual disturbances<\/li><li>fluid retention; monitor in patients with pre-existing cardiac or renal dysfunction<\/li><li>plasma triglycerides; patients with pre-existing hypertriglyceridemia<\/li><li>serum calcium; patients with pre-existing severe hypocalcemia or patients with breast cancer and bone metastases<\/li><li>thyroid function; patients with pre-existing hypothyroidism<\/li><\/ul>"},{"id":"214370-s-11","title":"How Supplied","mono":"<ul><li><b>Premarin Intravenous<\/b><br\/>Intravenous Powder for Solution: 25 MG<br\/><\/li><li><b>Premarin<\/b><br\/>Oral Tablet: 0.3 MG, 0.45 MG, 0.625 MG, 0.9 MG, 1.25 MG, 2.5 MG<br\/><\/li><li><b>Premarin Vaginal<\/b><br\/>Vaginal Cream: 0.625 MG\/GM<br\/><\/li><\/ul>"},{"id":"214370-s-12","title":"Toxicology","sub":[{"id":"214370-s-12-31","title":"Clinical Effects","mono":"<b>ORAL CONTRACEPTIVES <\/b><br\/>USES: To suppress the follicle-stimulating hormone luteinizing hormone sequence from the anterior pituitary, resulting in the suppression of ovulation and production of mucus that is less acceptable to spermatozoa. PHARMACOLOGY: An oral contraceptive acts by suppression of gonadotropins. TOXICOLOGY: There are no significant toxic effects from overdose. OVERDOSE: Abdominal pain, nausea, vomiting, headaches, breast tenderness, dysmenorrhea, arterial thromboembolism, hypertension, venous thrombosis, pulmonary embolus, cerebral thrombosis. ADVERSE EFFECTS: Nausea and vomiting with iron containing contraceptives in children, otherwise asymptomatic. <br\/>"},{"id":"214370-s-12-32","title":"Treatment","mono":"<b>ORAL CONTRACEPTIVES <\/b><br\/><ul><li>Support: MANAGEMENT OF MILD TO MODERATE TOXICITY: The vast majority of oral contraceptive overdoses require only supportive care. MANAGEMENT OF SEVERE TOXICITY: Severe toxicity is not expected in single substance oral contraceptive ingestion.<\/li><li>Decontamination: There is no need for GI decontamination.<\/li><li>Airway management: Patients with single substance oral contraceptive ingestion will not require airway management.<\/li><li>Antidote: None.<\/li><li>Enhanced elimination procedure: Hemodialysis and hemoperfusion are not of value.<\/li><li>Monitoring of patient: Concentrations of the hormones in oral contraceptives are not clinically useful. No routine laboratory studies are needed in most patients.<\/li><li>Patient disposition: HOME CRITERIA: Patients with inadvertent ingestions can be managed at home. If oral contraceptives containing iron are ingested, asymptomatic patients ingesting less than 40 mg\/kg elemental iron can be managed at home. OBSERVATION CRITERIA: The following patients should be sent to a healthcare facility for evaluation: Patients with self-harm ingestions; patients ingesting iron-containing oral contraceptives at a dose of more than 40 mg\/kg elemental iron or who have symptoms (nausea, vomiting, or other gastrointestinal complaints). ADMISSION CRITERIA: Patients with pure oral contraceptive overdoses do not need admission. Children with exposure to iron-containing products should follow the iron guidelines for admission. CONSULT CRITERIA: Consult a poison center or medical toxicologist for assistance in managing patients for any additional questions.<\/li><\/ul>"},{"id":"214370-s-12-33","title":"Range of Toxicity","mono":"<b>ORAL CONTRACEPTIVES <\/b><br\/>TOXICITY: A human toxic dose has not been established. Significant toxicity has not been reported after overdose. THERAPEUTIC DOSE: Oral contraceptives are available in various brands, doses, and formulations. <br\/>"}]},{"id":"214370-s-13","title":"Clinical Teaching","mono":"<ul><li>Discuss potential long-term adverse effects of hormone therapy including myocardial infarction, stroke, deep vein thrombosis, dementia, pulmonary embolism, or breast cancer.<\/li><li>This drug may cause edema, chloasma, hirsutism, loss of scalp hair, galactorrhea, change in weight, bloating, nausea, stomach cramps, vomiting, withdrawal bleeding, headache, migraine, depression, mood disturbance, abnormal menstruation, and swollen breasts.<\/li><li>Drug may also cause serious adverse effects such as gallbladder disease, pancreatitis, vision disorder, endometrial cancer, or ovarian cancer.<\/li><li>Inform patient that drug may exacerbate endometriosis.<\/li><li>Advise patient to report sudden onset migraine, diplopia, or partial or complete loss of vision, as drug may cause retinal vascular thrombosis.<\/li><li>Patient should not smoke while taking this drug.<\/li><li>Patients should not eat grapefruit or drink grapefruit juice while taking this drug.<\/li><\/ul>"}]}